Guggenheim Securities maintains a Buy status on Jazz Pharmaceuticals, PLC (NASDAQ: JAZZ), with a price target set at $210. This ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments Analyst EPS View

Cantor Fitzgerald Loweres PT to $165 for Jazz Pharmaceuticals (JAZZ) Following 1Q15 EPS MissMay 11, 2015 7:52 AM After-Hours Stock Movers 05/07: (NPTN) (SEDG) (DATA) Higher; (PLNR) (AVID) (SFM) Lower (more...)May 7, 2015 6:04 PM Jazz Pharmaceuticals (JAZZ) Misses Q1 EPS by 15cMay 7, 2015 4:16 PM Form 8-K Jazz Pharmaceuticals For: May 07May 7, 2015 4:15 PM Jazz Pharmaceuticals Announces First Quarter 2015 Financial ResultsMay 7, 2015 4:06 PM